Table VIII.
Isoforms | N+a | T+b | N/Tc | N/Td (Avg.) | N/Te (pooled) | ||||
---|---|---|---|---|---|---|---|---|---|
<1 | =1 | >1 | >3 | >10 | |||||
CYP1A2 | 15 (100%) | 8 (53%) | 0 | 0 | 0 | 3 (20%) | 12 (80%) | 20.5 | 28.5 |
CYP2A6 | 15 (100%) | 6 (40%) | 2 (13%) | 0 | 1 (7%) | 3 (20%) | 9 (60%) | 3.4 | 1.7 |
CYP2B6 | 11 (73%) | 1 (7%) | 0 | 5 (33%) | 0 | 0 | 10 (67%) | 4.2 | >4.3 |
CYP2C8 | 15 (100%) | 12 (80%) | 0 | 0 | 2 (13%) | 3 (20%) | 10 (67%) | 7.5 | 8.5 |
CYP2C9 | 15 (100%) | 15 (100%) | 0 | 0 | 3 (20%) | 5 (33%) | 7 (47%) | 6.2 | 8.2 |
CYP2C19 | 5 (33%) | 0 (0%) | 0 | 10 (67%) | 0 | 0 | 5 (33%) | >6.8 | >4.6 |
CYP2D6 | 15 (100%) | 15 (100%) | 0 | 0 | 3 (20%) | 9 (60%) | 3 (20%) | 4.7 | 4.7 |
CYP2E1 | 15 (100%) | 13 (87%) | 0 | 1 (7%) | 3 (20%) | 1 (7%) | 10 (67%) | 3.7 | 5.8 |
CYP3A4 | 15 (100%) | 8 (53%) | 0 | 0 | 1 (7%) | 3 (20%) | 11 (73%) | 18.2 | 16.7 |
UGT1A1 | 15 (100%) | 15 (100%) | 0 | 1 (7%) | 3 (20%) | 10 (67%) | 1 (7%) | 2.5 | 3.3 |
UGT1A4 | 15 (100%) | 13 (87%) | 0 | 1 (7%) | 3 (20%) | 5 (33%) | 6 (40%) | 4.2 | 4.2 |
UGT1A6 | 15 (100%) | 15 (100%) | 7 (47%) | 5 (33%) | 2 (14%) | 1 (7%) | 0 | 0.6 | 0.5 |
UGT1A9 | 15 (100%) | 15 (100%) | 3 (20%) | 4 (27%) | 3 (20%) | 5 (33%) | 0 | 1.8 | 1.9 |
UGT2B7 | 15 (100%) | 15 (100%) | 0 | 0 | 3 (20%) | 3 (20%) | 9 (60%) | 6.6 | 6.9 |
Number (percentage) of positive samples prepared from pericarcinomatous tissues in which the target protein can be detected.
Number (percentage) of positive samples prepared from tumor tissues in which the target protein can be detected.
Number (percentage) of patients with certain fold change (<1,=1,>1,>3 or >10-fold) of protein amount in their tumor tissues compared with matched pericarcinomatous tissues.
Variations in average expression levels of CYPs or UGTs in 15 tumor tissues compared with pericarcinomatous tissues.
Variations in expression levels of CYPs or UGTs in tHLMs-pooled compared nHLMs-pooled.